News Release

PURMX Therapeutics, Inc.（Headquartered in Hiroshima, Japan; President and CEO: Hidetoshi Tahara）is pleased to announce that we have commenced a proof of concept (PoC) to identify target molecules and elucidate the mechanism of action of our naturally occurring microRNA-based nucleic acid therapeutics by leveraging “Drug Discovery AI Factory” (hereinafter “DDAIF”), an AI-based drug discovery support service provided by FRONTEO, Inc. (Headquartered in Tokyo, Japan; President &

PURMX Therapeutics, Inc. (Headquartered in Hiroshima, Japan; President and CEO: Hidetoshi Tahara; hereinafter "the Company") is pleased to announce the completion of both the Single Ascending Dose (SAD) study (Protocol No.: MIRX002-01) and the Multiple Ascending Dose (MAD) study (Protocol No.: MIRX002-02), investigator-initiated clinical trials for malignant pleural mesothelioma using natural-type microRNA replacement therapy, for which the Company supplied the investigationa

PURMX Therapeutics, Inc. (Headquarters: Hiroshima-city, Hiroshima; President & CEO: Hidetoshi Tahara) is pleased to announce that it has...